X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs STERLING BIOTECH - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH STERLING BIOTECH PANACEA BIOTECH/
STERLING BIOTECH
 
P/E (TTM) x 171.2 -1.9 - View Chart
P/BV x 3.8 0.1 5,086.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   STERLING BIOTECH
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
STERLING BIOTECH
Dec-13
PANACEA BIOTECH/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs14911 1,416.2%   
Low Rs823 2,420.6%   
Sales per share (Unadj.) Rs84.126.8 313.9%  
Earnings per share (Unadj.) Rs-18.3-15.0 122.4%  
Cash flow per share (Unadj.) Rs-6.7-5.5 122.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.754.9 152.5%  
Shares outstanding (eoy) m61.25267.87 22.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.40.3 529.5%   
Avg P/E ratio x-6.3-0.5 1,357.8%  
P/CF ratio (eoy) x-17.2-1.3 1,355.2%  
Price / Book Value ratio x1.40.1 1,089.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0741,862 380.0%   
No. of employees `0002.81.4 203.1%   
Total wages/salary Rs m1,449547 265.0%   
Avg. sales/employee Rs Th1,874.15,303.3 35.3%   
Avg. wages/employee Rs Th527.0403.8 130.5%   
Avg. net profit/employee Rs Th-407.7-2,959.0 13.8%   
INCOME DATA
Net Sales Rs m5,1547,181 71.8%  
Other income Rs m10043 234.3%   
Total revenues Rs m5,2547,223 72.7%   
Gross profit Rs m-766947 -80.9%  
Depreciation Rs m7112,543 28.0%   
Interest Rs m1,5034,377 34.3%   
Profit before tax Rs m-2,881-5,931 48.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17-1,924 -0.9%   
Profit after tax Rs m-1,121-4,007 28.0%  
Gross profit margin %-14.913.2 -112.8%  
Effective tax rate %-0.632.4 -1.8%   
Net profit margin %-21.8-55.8 39.0%  
BALANCE SHEET DATA
Current assets Rs m3,81014,335 26.6%   
Current liabilities Rs m8,36549,809 16.8%   
Net working cap to sales %-88.4-494.0 17.9%  
Current ratio x0.50.3 158.3%  
Inventory Days Days156403 38.6%  
Debtors Days Days67171 39.4%  
Net fixed assets Rs m14,48055,432 26.1%   
Share capital Rs m61268 22.9%   
"Free" reserves Rs m90313,935 6.5%   
Net worth Rs m5,12714,701 34.9%   
Long term debt Rs m5,8329,478 61.5%   
Total assets Rs m19,43373,988 26.3%  
Interest coverage x-0.9-0.4 258.2%   
Debt to equity ratio x1.10.6 176.4%  
Sales to assets ratio x0.30.1 273.3%   
Return on assets %2.00.5 392.1%  
Return on equity %-21.9-27.3 80.2%  
Return on capital %3.6-6.4 -56.6%  
Exports to sales %24.525.9 94.7%   
Imports to sales %10.20.2 5,993.5%   
Exports (fob) Rs m1,2641,860 68.0%   
Imports (cif) Rs m52512 4,301.6%   
Fx inflow Rs m1,5391,860 82.8%   
Fx outflow Rs m94225 3,784.7%   
Net fx Rs m5971,835 32.5%   
CASH FLOW
From Operations Rs m5991,719 34.9%  
From Investments Rs m-438-3,148 13.9%  
From Financial Activity Rs m-3031,426 -21.2%  
Net Cashflow Rs m-141-3 4,155.9%  

Share Holding

Indian Promoters % 74.5 33.9 219.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 0.0 -  
FIIs % 1.3 9.9 13.1%  
ADR/GDR % 0.0 16.9 -  
Free float % 23.6 39.3 60.1%  
Shareholders   10,259 21,482 47.8%  
Pledged promoter(s) holding % 35.1 55.9 62.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON LTD  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 23, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS